A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 2

Conditions

Anxiety Disorders

Social Anxiety Disorder

Treatments

Drug: paroxetine

Study type

Interventional

Funder types

Industry

Identifiers

NKF100110

Details and patient eligibility

About

The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder

Enrollment

242 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with Generalized Social Anxiety Disorder as the primary diagnosis.
If female, must commit to consistent and correct use of an acceptable method of birth control.

Exclusion criteria

Patients with any other psychiatric disorder as a primary diagnosis or within 6 months prior to screening.
Patients with Body Dysmophic Disorder, Schizophrenia, Schizoaffective Disorder, or a Bipolar Disorder.
Patients who pose a current suicidal or homicidal risk or have made a suicide attempt within the past 6 months or have ever been homicidal.
Patients who have a positive urine test at screen for illegal drug use and/or a history of substance abuse or dependence (alcohol or drugs) within the past 12 months.
Patients with an unstable medical disorder.
Female patients who are pregnant, lactating, or planning to become pregnant during a specified time during the study.
Patients who are taking other psychoactive medications.